Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

54.21
-1.4400-2.59%
Post-market: 54.20-0.0100-0.02%16:26 EDT
Volume:2.15M
Turnover:118.11M
Market Cap:9.01B
PE:-15.58
High:56.16
Open:55.94
Low:54.16
Close:55.65
52wk High:86.74
52wk Low:50.01
Shares:166.18M
Float Shares:161.92M
Volume Ratio:0.48
T/O Rate:1.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4800
EPS(LYR):-2.3812
ROE:-105.50%
ROA:-12.42%
PB:20.49
PE(LYR):-22.77

Loading ...

Ultragenyx Hits Record Low After Rare Disease Drug Trial Failure

Reuters
·
Sep 03

Ionis to Join Wells Fargo, Morgan Stanley Healthcare Investor Conference Fireside Chats

Reuters
·
Sep 03

Trump Administration Announces Drug Pricing Deals with CSL, Astellas and Others

Reuters
·
Sep 01

Ionis Pharmaceuticals Price Target Maintained with a $115.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 31

Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Aug 31

Jefferies sees neutral to negative read-through to Alnylam from AstraZeneca data

TIPRANKS
·
Aug 28

Alnylam, Ionis Fall as Heart-Drug Data Raise Doubts over Combination Treatment

Reuters
·
Aug 28

Ionis Pharmaceuticals, Inc. : Bmo Initiates Coverage with Market Perform Rating; Price Target $60

THOMSON REUTERS
·
Aug 19

BMO Capital starts Ionis at Market Perform pending better visibility

TIPRANKS
·
Aug 19

Analysts Conflicted on These Healthcare Names: Definium Therapeutics (DFTX), Ionis Pharmaceuticals (IONS) and Sutro Biopharma (STRO)

TIPRANKS
·
Aug 15

Ionis Pharmaceuticals (IONS) Receives a Buy from Wells Fargo

TIPRANKS
·
Aug 14

Ionis Pharmaceuticals Earnings Call Highlights Pipeline And Growth

TIPRANKS
·
Aug 12

J.P. Morgan Reaffirms Their Buy Rating on Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Aug 10

Novartis Might Struggle to Clear Bar in Cholesterol Drug Trial

Dow Jones
·
Aug 10

Ionis Pharmaceuticals (IONS) Receives a Hold from Stifel Nicolaus

TIPRANKS
·
Aug 03

Ionis Director Michael R. Hayden Reports Acquisition of 20,000 Common Shares Worth $1,059,000

Reuters
·
Aug 01

Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanks

Benzinga Earnings
·
Jul 31

Ionis Pharmaceuticals: Strong Commercial Momentum and Late‑Stage Pipeline Catalysts Drive Buy Rating

TIPRANKS
·
Jul 31

Ionis Pharmaceuticals is Maintained at Overweight by Wells Fargo

Dow Jones
·
Jul 30

Alnylam Q2 Revenue Rises 67% on Increased Demand for Amvuttra

Reuters
·
Jul 30